<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<xbrli:xbrl xml:lang="en" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:gsd="http://xbrl.dcca.dk/gsd" xmlns:cmn="http://xbrl.dcca.dk/cmn" xmlns:fsa="http://xbrl.dcca.dk/fsa" xmlns:sob="http://xbrl.dcca.dk/sob" xmlns:arr="http://xbrl.dcca.dk/arr" xmlns:mrv="http://xbrl.dcca.dk/mrv" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">
  <link:schemaRef xlink:href="http://archprod.service.eogs.dk/taxonomy/20221001/entryDanishGAAPBalanceSheetAccountFormIncomeStatementByNatureIncludingManagementsReviewStatisticsAndTax20221001.xsd" xlink:type="simple" />
  <xbrli:context id="ctx-1">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">26688949</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-01-01</xbrli:startDate>
      <xbrli:endDate>2023-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="ctx-2">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">26688949</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2022-01-01</xbrli:startDate>
      <xbrli:endDate>2022-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="ctx-3">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">26688949</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="ctx-4">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">26688949</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="ctx-5">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">26688949</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-12-31</xbrli:instant>
    </xbrli:period>
    <xbrli:scenario>
      <xbrldi:explicitMember dimension="fsa:ClassesOfEquityDimension">fsa:ContributedCapitalMember</xbrldi:explicitMember>
    </xbrli:scenario>
  </xbrli:context>
  <xbrli:context id="ctx-6">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">26688949</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-01-01</xbrli:startDate>
      <xbrli:endDate>2023-12-31</xbrli:endDate>
    </xbrli:period>
    <xbrli:scenario>
      <xbrldi:explicitMember dimension="fsa:ClassesOfEquityDimension">fsa:ContributedCapitalMember</xbrldi:explicitMember>
    </xbrli:scenario>
  </xbrli:context>
  <xbrli:context id="ctx-7">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">26688949</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-12-31</xbrli:instant>
    </xbrli:period>
    <xbrli:scenario>
      <xbrldi:explicitMember dimension="fsa:ClassesOfEquityDimension">fsa:ContributedCapitalMember</xbrldi:explicitMember>
    </xbrli:scenario>
  </xbrli:context>
  <xbrli:context id="ctx-8">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">26688949</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-12-31</xbrli:instant>
    </xbrli:period>
    <xbrli:scenario>
      <xbrldi:explicitMember dimension="fsa:ClassesOfEquityDimension">fsa:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:scenario>
  </xbrli:context>
  <xbrli:context id="ctx-9">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">26688949</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-01-01</xbrli:startDate>
      <xbrli:endDate>2023-12-31</xbrli:endDate>
    </xbrli:period>
    <xbrli:scenario>
      <xbrldi:explicitMember dimension="fsa:ClassesOfEquityDimension">fsa:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:scenario>
  </xbrli:context>
  <xbrli:context id="ctx-10">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">26688949</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-12-31</xbrli:instant>
    </xbrli:period>
    <xbrli:scenario>
      <xbrldi:explicitMember dimension="fsa:ClassesOfEquityDimension">fsa:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:scenario>
  </xbrli:context>
  <xbrli:context id="ctx-11">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">26688949</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2022-12-31</xbrli:instant>
    </xbrli:period>
    <xbrli:scenario>
      <xbrldi:explicitMember dimension="fsa:ClassesOfEquityDimension">fsa:ProposedDividendRecognisedInEquityMember</xbrldi:explicitMember>
    </xbrli:scenario>
  </xbrli:context>
  <xbrli:context id="ctx-12">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">26688949</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-01-01</xbrli:startDate>
      <xbrli:endDate>2023-12-31</xbrli:endDate>
    </xbrli:period>
    <xbrli:scenario>
      <xbrldi:explicitMember dimension="fsa:ClassesOfEquityDimension">fsa:ProposedDividendRecognisedInEquityMember</xbrldi:explicitMember>
    </xbrli:scenario>
  </xbrli:context>
  <xbrli:context id="ctx-13">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">26688949</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2023-12-31</xbrli:instant>
    </xbrli:period>
    <xbrli:scenario>
      <xbrldi:explicitMember dimension="fsa:ClassesOfEquityDimension">fsa:ProposedDividendRecognisedInEquityMember</xbrldi:explicitMember>
    </xbrli:scenario>
  </xbrli:context>
  <xbrli:context id="ctx-14">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">26688949</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-01-01</xbrli:startDate>
      <xbrli:endDate>2023-12-31</xbrli:endDate>
    </xbrli:period>
    <xbrli:scenario>
      <xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfExecutiveBoardDimension">
        <cmn:memberOfBoardIdentifier>1</cmn:memberOfBoardIdentifier>
      </xbrldi:typedMember>
    </xbrli:scenario>
  </xbrli:context>
  <xbrli:context id="ctx-15">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">26688949</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-01-01</xbrli:startDate>
      <xbrli:endDate>2023-12-31</xbrli:endDate>
    </xbrli:period>
    <xbrli:scenario>
      <xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfSupervisoryBoardDimension">
        <cmn:memberOfBoardIdentifier>1</cmn:memberOfBoardIdentifier>
      </xbrldi:typedMember>
    </xbrli:scenario>
  </xbrli:context>
  <xbrli:context id="ctx-16">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">26688949</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-01-01</xbrli:startDate>
      <xbrli:endDate>2023-12-31</xbrli:endDate>
    </xbrli:period>
    <xbrli:scenario>
      <xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfSupervisoryBoardDimension">
        <cmn:memberOfBoardIdentifier>2</cmn:memberOfBoardIdentifier>
      </xbrldi:typedMember>
    </xbrli:scenario>
  </xbrli:context>
  <xbrli:context id="ctx-17">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">26688949</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-01-01</xbrli:startDate>
      <xbrli:endDate>2023-12-31</xbrli:endDate>
    </xbrli:period>
    <xbrli:scenario>
      <xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfSupervisoryBoardDimension">
        <cmn:memberOfBoardIdentifier>3</cmn:memberOfBoardIdentifier>
      </xbrldi:typedMember>
    </xbrli:scenario>
  </xbrli:context>
  <xbrli:context id="ctx-18">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.dcca.dk/cvr">26688949</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2023-01-01</xbrli:startDate>
      <xbrli:endDate>2023-12-31</xbrli:endDate>
    </xbrli:period>
    <xbrli:scenario>
      <xbrldi:typedMember dimension="cmn:IdentificationOfAuditorDimension">
        <cmn:auditorIdentifier>1</cmn:auditorIdentifier>
      </xbrldi:typedMember>
    </xbrli:scenario>
  </xbrli:context>
  <xbrli:unit id="dkk">
    <xbrli:measure>iso4217:DKK</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="pure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <gsd:NameAndSurnameOfChairmanOfGeneralMeeting contextRef="ctx-1" xml:lang="en">Ana Isabel Infante Gonzalez De La Aleja</gsd:NameAndSurnameOfChairmanOfGeneralMeeting>
  <sob:StatementByExecutiveAndSupervisoryBoards contextRef="ctx-1" xml:lang="en">The Board of Directors and Executive Board have today discussed and approved the Annual Report of UCB NORDIC A/S for the financial year 1 January - 31 December 2023.The annual report is prepared in accordance with the Danish Financial Statements Act.In our opinion the financial statements give a true and  fair  view  of  the  Company's  assets,  liabilities and  financial  position  at  31  December  2023  and  of  the  results  of  the  company's  operations  for  the financial year 1 January - 31 December 2023.Further,  in  our  opinion,  the  Management's  review  gives  a  fair  review  of  the  development  in  the Company’s operations and financial matters, of the results for the year and of the Company’s financial position.We recommend that the Annual Report be approved at the Annual General Meeting.</sob:StatementByExecutiveAndSupervisoryBoards>
  <sob:PlaceOfSignatureOfStatement contextRef="ctx-1" xml:lang="en">Copenhagen,</sob:PlaceOfSignatureOfStatement>
  <cmn:NameAndSurnameOfMemberOfExecutiveBoard contextRef="ctx-14" xml:lang="en">Mari-Ann Retz</cmn:NameAndSurnameOfMemberOfExecutiveBoard>
  <cmn:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="ctx-15" xml:lang="en">Ana Isabel Infante Gonzalez De La Aleja </cmn:NameAndSurnameOfMemberOfSupervisoryBoard>
  <cmn:TitleOfMemberOfSupervisoryBoard contextRef="ctx-15" xml:lang="en">Chairman</cmn:TitleOfMemberOfSupervisoryBoard>
  <cmn:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="ctx-16" xml:lang="en">Per Ove Jonas Berg</cmn:NameAndSurnameOfMemberOfSupervisoryBoard>
  <cmn:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="ctx-17" xml:lang="en">Afshin Risseh</cmn:NameAndSurnameOfMemberOfSupervisoryBoard>
  <arr:AddresseeOfAuditorsReportOnAuditedFinancialStatements contextRef="ctx-1" xml:lang="en">To the shareholder of UCB NORDIC A/S </arr:AddresseeOfAuditorsReportOnAuditedFinancialStatements>
  <arr:OpinionOnAuditedFinancialStatements contextRef="ctx-1" xml:lang="en">In our opinion, the Financial Statements give a true and fair view of the Company’s assets, liabilities and financial position of the Company at 31 December 2023, and of the results of the Company’s operations for the financial year 1 January - 31 December 2023 in accordance with the Danish Financial Statements Act.We  have  audited  the  Financial  Statements  of  UCB  NORDIC A/S  for  the  financial  year  1  January  - 31 December 2023, which comprise income statement, balance sheet, statement of changes in equity and notes, including a summary of significant accounting policies.</arr:OpinionOnAuditedFinancialStatements>
  <arr:DescriptionOfQualificationsOfAuditedFinancialStatements contextRef="ctx-1" xml:lang="en">We  conducted  our  audit  in  accordance  with  International  Standards  on  Auditing  (ISAs)  and  the additional  requirements  applicable  in  Denmark.  Our  responsibilities  under  those  standards  and requirements  are  further  described  in  the  Auditor’s  Responsibilities  for  the  Audit  of  the  Financial Statements  section  of  our  report.  We  are  independent  of  the  Company  in  accordance  with  the International  Ethics  Standards  Board  for  Accountants’  Code  of  Ethics  for  Professional  Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.</arr:DescriptionOfQualificationsOfAuditedFinancialStatements>
  <arr:StatementOnManagementsReviewAuditorsReportOnAuditedFinancialStatements contextRef="ctx-1" xml:lang="en">Management is responsible for Management’s Review.Our opinion on the financial statements does not cover Management’s Review, and we do not express any form of assurance conclusion thereon.In  connection  with  our  audit  of  the  financial  statements,  our  responsibility  is  to  read  Management’s Review and, in doing so, consider whether Management’s Review is materially inconsistent with the financial statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated.Moreover, it is our responsibility to consider whether Management’s Review provides the information required under the Danish Financial Statements Act.Based on the work we have performed, in our view, Management’s Review is in accordance with the Financial  Statements  and  has  been  prepared  in  accordance  with  the  requirements  of  the  Danish Financial Statements Act. We did not identify any material misstatement in Management’s Review.</arr:StatementOnManagementsReviewAuditorsReportOnAuditedFinancialStatements>
  <arr:StatementOfExecutiveAndSupervisoryBoardsResponsibilityForFinancialStatements contextRef="ctx-1" xml:lang="en">Management is responsible for the preparation of Financial Statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.In preparing the financial statements, Management is responsible for assessing the Company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the  going  concern  basis  of  accounting  in  preparing  the  financial  statements  unless  Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.</arr:StatementOfExecutiveAndSupervisoryBoardsResponsibilityForFinancialStatements>
  <arr:StatementOfAuditorsResponsibilityForAuditAndAuditPerformed contextRef="ctx-1" xml:lang="en">Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or  error, and to  issue  an  auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that  an  audit  conducted  in  accordance  with  ISAs  and  the  additional  requirements  applicable  in Denmark  will  always  detect  a  material  misstatement  when  it  exists.  Misstatements  can  arise  from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected  to  influence  the  economic  decisions  of  users  taken  on  the  basis  of  these  financial statements.As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark,  we  exercise  professional  judgment  and  maintain  professional  skepticism  throughout  the audit. We also:– Identify and assess the risks of material misstatement of the financial statements, whether due to fraud  or  error,  design  and  perform  audit  procedures  responsive  to  those  risks,  and  obtain  audit evidence  that  is  sufficient  and  appropriate  to  provide  a  basis  for  our  opinion.  The  risk  of  not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve  collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.– Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control.– Evaluate the appropriateness of accounting  policies  used and the reasonableness of accounting estimates and related disclosures made by Management.– Conclude on the appropriateness of Management’s use of the going concern basis of accounting in  pre-paring  the  financial  statements  and,  based  on  the  audit  evidence  obtained,  whether  a material  uncertainty  exists  related  to  events  or conditions  that  may  cast  significant  doubt  on the Company’s ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor’s report to the related disclosures in the financial statements  or,  if  such  disclosures  are  inadequate,  to  modify  our  opinion.  Our  conclusions  are based on the audit evidence obtained up to the date of our auditor’s report. However, future events or conditions may cause the Company to cease to continue as a going concern.– Evaluate the overall presentation, structure and contents of the financial statements, including the disclosures,  and  whether  the  financial  statements  represent  the  underlying  transactions  and events in a manner that gives a true and fair view.We communicate with those charged with governance regarding, among other matters, the planned scope  and  timing  of  the  audit  and  significant  audit  findings,  including  any  significant  deficiencies  in internal control that we identify during our audit.</arr:StatementOfAuditorsResponsibilityForAuditAndAuditPerformed>
  <arr:SignatureOfAuditorsPlace contextRef="ctx-1" xml:lang="en">København Ø,</arr:SignatureOfAuditorsPlace>
  <cmn:NameOfAuditFirm contextRef="ctx-18" xml:lang="en">MazarsStatsautoriseret Revisionspartnerselskab</cmn:NameOfAuditFirm>
  <cmn:IdentificationNumberCvrOfAuditFirm contextRef="ctx-18">31061741</cmn:IdentificationNumberCvrOfAuditFirm>
  <cmn:NameAndSurnameOfAuditor contextRef="ctx-18" xml:lang="en">Karsten Vedel</cmn:NameAndSurnameOfAuditor>
  <cmn:DescriptionOfAuditor contextRef="ctx-18" xml:lang="en">State Authorised Public Accountant</cmn:DescriptionOfAuditor>
  <cmn:IdentificationNumberOfAuditor contextRef="ctx-18">mne47841</cmn:IdentificationNumberOfAuditor>
  <gsd:NameOfReportingEntity contextRef="ctx-1" xml:lang="en">UCB NORDIC A/S</gsd:NameOfReportingEntity>
  <gsd:AddressOfReportingEntityStreetName contextRef="ctx-1" xml:lang="en">Edvard Thomsens Vej </gsd:AddressOfReportingEntityStreetName>
  <gsd:AddressOfReportingEntityStreetBuildingIdentifier contextRef="ctx-1" xml:lang="en">14, 7.</gsd:AddressOfReportingEntityStreetBuildingIdentifier>
  <gsd:AddressOfReportingEntityPostCodeIdentifier contextRef="ctx-1" xml:lang="en">2300</gsd:AddressOfReportingEntityPostCodeIdentifier>
  <gsd:AddressOfReportingEntityDistrictName contextRef="ctx-1" xml:lang="en">København S</gsd:AddressOfReportingEntityDistrictName>
  <gsd:TelephoneNumberOfReportingEntity contextRef="ctx-1" xml:lang="en">32462400</gsd:TelephoneNumberOfReportingEntity>
  <gsd:FaxNumberOfReportingEntity contextRef="ctx-1" xml:lang="en">32462401</gsd:FaxNumberOfReportingEntity>
  <gsd:HomepageOfReportingEntity contextRef="ctx-1">www.ucb.com</gsd:HomepageOfReportingEntity>
  <gsd:IdentificationNumberCvrOfReportingEntity contextRef="ctx-1">26688949</gsd:IdentificationNumberCvrOfReportingEntity>
  <gsd:RegisteredOfficeOfReportingEntity contextRef="ctx-1" xml:lang="en">Copenhagen</gsd:RegisteredOfficeOfReportingEntity>
  <gsd:AddressOfAuditorStreetName contextRef="ctx-18" xml:lang="en">Midtermolen</gsd:AddressOfAuditorStreetName>
  <gsd:AddressOfAuditorStreetBuildingIdentifier contextRef="ctx-18" xml:lang="en">1, 2. tv.</gsd:AddressOfAuditorStreetBuildingIdentifier>
  <gsd:AddressOfAuditorPostCodeIdentifier contextRef="ctx-18" xml:lang="en">2100</gsd:AddressOfAuditorPostCodeIdentifier>
  <gsd:AddressOfAuditorDistrictName contextRef="ctx-18" xml:lang="en">København Ø</gsd:AddressOfAuditorDistrictName>
  <mrv:ManagementsReview contextRef="ctx-1" xml:lang="en">Financial highlightsDKK'0002023 2022 2021 2020 2019Key figuresGross profit/loss  66,895    61,499    60,527    46,217    39,541 Ordinary operating profit/loss  5,564    5,333    4,032    4,948    4,514 Profit/loss from financial income   5,284    5,128    3,817    4,650    4,246 and expensesProfit/loss for the year  3,888    4,004    3,016    3,721    3,591 Total assets  65,918    57,654    59,202    60,523    58,816 Equity  16,106    15,118    14,114    11,094    10,573 Investment in property, plant and   34    —    —    —    — equipmentRatiosReturn on equity 25 %  27 %  24 %  34 %  34 %Solvency ratio 24 %  26 %  24 %  18 %  18 %The financial ratios have been calculated as follows:Return on equity Profit/loss for the year x 100Average equitySolvency ratio Equity at year end x 100Total assets at year endUncertainty regarding recognition and measurementThe  valuation  of  assets  and  liabilities  is  made  in  accordance  with  current  accounting  policies,  and Management  of  the  Company  is  of  the  opinion  that  no  uncertainty  is  related  to  recognition  and measurement.Unusual circumstancesThere  have  been  no  unusual circumstances  affecting recognition and  measurement  in  the  financial year 2023.Profit/loss for the year (including comparison with forecasts previously announced)Our  portfolio  in  Denmark  is  comprised  of  our  biologic  brands  for  Immunology  diseases  Cimzia, Bimzelx and within the Bone Builder environment Evenity.The  Epilepsy  portfolio  is  comprised  of  the  drugs  Briviact,  Vimpat,  Keppra  and  Fintepla,  a  recently launched  product  for  treatment  of  seizures  associated  with  Dravet  syndrome  (DS)  and  Lennox-Gastaut  syndrome.  Next  to  Epilepsy  products  we  have  Neupro  helping  people  with  Parkinson disease. As part of established brands we commercialize Zyrtec, Xyzal as treatment for allergies and Xyrem used to treat adults who suffer from narcolepsy.  The Company's revenue increased by 23% in 2023 compared to previous year. Cimzia increased by 8% versus last year, in line with expectations as we won the tender for 2023 like in 2022.In  November  2022  we  launched  Bimzelx  for  people  suffering from  Psoriasis  with  very  good  results (2M€) in 2023 due to a favorable ranking.Evenity  had  an  exponential  growth  of  52%  which  triggered  an  increase  of  1.1M€  versus  last  year sales which was almost the same level as last year’s growth.The  overall  Neurology  portfolio  revenues  decreased  due  to  the  loss  of  exclusivity  of  Vimpat  in September 2022 which generated a loss of 1.2M€ versus 2022. The new product Fintepla created a growth of 0.3M€ leading to overall Fintepla sales of 1.3M€ in 2023. The overall neurology revenues are impacted by Parallel Import except for Fintepla.In Established brands the revenues were in line with last year performance.The profit for 2023 amounts to DKK 3,888 thousand versus DKK 4,004 thousand in 2022 which is in line with previous year.The financial year was well above the forecast due to a strong performance of Bimzelx and Fintepla.Risk management (operating and financial risk)A global Risk Management policy, applicable for the whole UCB Group and its affiliates worldwide,describes the UCB Group's commitment to provide an effective risk management system across thecompany in order to minimize its exposure to risks that could threaten the UCB Group's corporate objectives.The Board of Directors is responsible for approving the UCB Group's strategy, goals and objectives and overseeing the establishment, implementation and review of the Group's risk management system.Operating reviewThe  Board  is  assisted  by  the  Audit  Committee  in  its  responsibility  for  the  appreciation  of  risk management.  The  Audit  Committee  examines  on  a  regular  basis  the  areas  where  risks  could significantly  affect  the  financial  situation  or  reputation  of  the  UCB  Group.  The  Audit  Committee monitors the overall risk management process of UCB.The  main  risks  faced  by  the  Company  relate  to  financial  risks  in  particular  pricing  and  foreign exchange risk.The Company's performance is impacted by parallel trade.Other insurable risks are insured by the Company to the extent that the directors consider appropriate having due regard to the considered impact from said risk.Environmental mattersThe Company's activities do not have any material environmental impact.Research and development activitiesThe Company had some local clinical trial activities in 2023.OutlookIn 2023 no special events or exceptional items of income and expense from the normal activities have taken place,which have influenced or could influence the future expectations for UCB NORDIC A/S. Therefore, we expect no changes in the financing environment as well. We expect a result before tax for 2024 of approximately the same amount as in 2023.</mrv:ManagementsReview>
  <mrv:DescriptionOfPrimaryActivitiesOfEntity contextRef="ctx-1" xml:lang="en">Principal activity The objective of the Company is to carry out business activity in the fields of biotechnology, medicine and chemistry and related areas as defined by the board.</mrv:DescriptionOfPrimaryActivitiesOfEntity>
  <fsa:GrossResult unitRef="dkk" contextRef="ctx-1" decimals="-3">66895000</fsa:GrossResult>
  <fsa:GrossResult unitRef="dkk" contextRef="ctx-2" decimals="-3">61499000</fsa:GrossResult>
  <fsa:EmployeeBenefitsExpense unitRef="dkk" contextRef="ctx-1" decimals="-3">61326000</fsa:EmployeeBenefitsExpense>
  <fsa:EmployeeBenefitsExpense unitRef="dkk" contextRef="ctx-2" decimals="-3">56120000</fsa:EmployeeBenefitsExpense>
  <fsa:DepreciationAmortisationExpenseAndImpairmentLossesOfPropertyPlantAndEquipmentAndIntangibleAssetsRecognisedInProfitOrLoss unitRef="dkk" contextRef="ctx-1" decimals="-3">5000</fsa:DepreciationAmortisationExpenseAndImpairmentLossesOfPropertyPlantAndEquipmentAndIntangibleAssetsRecognisedInProfitOrLoss>
  <fsa:DepreciationAmortisationExpenseAndImpairmentLossesOfPropertyPlantAndEquipmentAndIntangibleAssetsRecognisedInProfitOrLoss unitRef="dkk" contextRef="ctx-2" decimals="-3">46000</fsa:DepreciationAmortisationExpenseAndImpairmentLossesOfPropertyPlantAndEquipmentAndIntangibleAssetsRecognisedInProfitOrLoss>
  <fsa:ProfitLossFromOrdinaryOperatingActivities unitRef="dkk" contextRef="ctx-1" decimals="-3">5564000</fsa:ProfitLossFromOrdinaryOperatingActivities>
  <fsa:ProfitLossFromOrdinaryOperatingActivities unitRef="dkk" contextRef="ctx-2" decimals="-3">5333000</fsa:ProfitLossFromOrdinaryOperatingActivities>
  <fsa:OtherFinanceIncome unitRef="dkk" contextRef="ctx-1" decimals="-3">581000</fsa:OtherFinanceIncome>
  <fsa:OtherFinanceIncome unitRef="dkk" contextRef="ctx-2" decimals="-3">113000</fsa:OtherFinanceIncome>
  <fsa:OtherFinanceExpenses unitRef="dkk" contextRef="ctx-1" decimals="-3">861000</fsa:OtherFinanceExpenses>
  <fsa:OtherFinanceExpenses unitRef="dkk" contextRef="ctx-2" decimals="-3">318000</fsa:OtherFinanceExpenses>
  <fsa:ProfitLossFromOrdinaryActivitiesBeforeTax unitRef="dkk" contextRef="ctx-1" decimals="-3">5284000</fsa:ProfitLossFromOrdinaryActivitiesBeforeTax>
  <fsa:ProfitLossFromOrdinaryActivitiesBeforeTax unitRef="dkk" contextRef="ctx-2" decimals="-3">5128000</fsa:ProfitLossFromOrdinaryActivitiesBeforeTax>
  <fsa:TaxExpense unitRef="dkk" contextRef="ctx-1" decimals="-3">1396000</fsa:TaxExpense>
  <fsa:TaxExpense unitRef="dkk" contextRef="ctx-2" decimals="-3">1124000</fsa:TaxExpense>
  <fsa:ProfitLoss unitRef="dkk" contextRef="ctx-1" decimals="-3">3888000</fsa:ProfitLoss>
  <fsa:ProfitLoss unitRef="dkk" contextRef="ctx-2" decimals="-3">4004000</fsa:ProfitLoss>
  <fsa:FixturesFittingsToolsAndEquipment unitRef="dkk" contextRef="ctx-3" decimals="-3">34000</fsa:FixturesFittingsToolsAndEquipment>
  <fsa:FixturesFittingsToolsAndEquipment unitRef="dkk" contextRef="ctx-4" decimals="-3">3000</fsa:FixturesFittingsToolsAndEquipment>
  <fsa:OtherLongtermReceivables unitRef="dkk" contextRef="ctx-3" decimals="-3">533000</fsa:OtherLongtermReceivables>
  <fsa:OtherLongtermReceivables unitRef="dkk" contextRef="ctx-4" decimals="-3">528000</fsa:OtherLongtermReceivables>
  <fsa:NoncurrentAssets unitRef="dkk" contextRef="ctx-3" decimals="-3">567000</fsa:NoncurrentAssets>
  <fsa:NoncurrentAssets unitRef="dkk" contextRef="ctx-4" decimals="-3">531000</fsa:NoncurrentAssets>
  <fsa:ManufacturedGoodsAndGoodsForResale unitRef="dkk" contextRef="ctx-3" decimals="-3">13615000</fsa:ManufacturedGoodsAndGoodsForResale>
  <fsa:ManufacturedGoodsAndGoodsForResale unitRef="dkk" contextRef="ctx-4" decimals="-3">7695000</fsa:ManufacturedGoodsAndGoodsForResale>
  <fsa:ShorttermTradeReceivables unitRef="dkk" contextRef="ctx-3" decimals="-3">20838000</fsa:ShorttermTradeReceivables>
  <fsa:ShorttermTradeReceivables unitRef="dkk" contextRef="ctx-4" decimals="-3">17581000</fsa:ShorttermTradeReceivables>
  <fsa:ShorttermReceivablesFromGroupEnterprises unitRef="dkk" contextRef="ctx-3" decimals="-3">22060000</fsa:ShorttermReceivablesFromGroupEnterprises>
  <fsa:ShorttermReceivablesFromGroupEnterprises unitRef="dkk" contextRef="ctx-4" decimals="-3">19796000</fsa:ShorttermReceivablesFromGroupEnterprises>
  <fsa:DeferredIncomeAssets unitRef="dkk" contextRef="ctx-3" decimals="-3">179000</fsa:DeferredIncomeAssets>
  <fsa:DeferredIncomeAssets unitRef="dkk" contextRef="ctx-4" decimals="-3">169000</fsa:DeferredIncomeAssets>
  <fsa:CurrentDeferredTaxAssets unitRef="dkk" contextRef="ctx-3" decimals="-3">1441000</fsa:CurrentDeferredTaxAssets>
  <fsa:CurrentDeferredTaxAssets unitRef="dkk" contextRef="ctx-4" decimals="-3">1100000</fsa:CurrentDeferredTaxAssets>
  <fsa:ShorttermReceivables unitRef="dkk" contextRef="ctx-3" decimals="-3">44518000</fsa:ShorttermReceivables>
  <fsa:ShorttermReceivables unitRef="dkk" contextRef="ctx-4" decimals="-3">38646000</fsa:ShorttermReceivables>
  <fsa:CashAndCashEquivalents unitRef="dkk" contextRef="ctx-3" decimals="-3">7218000</fsa:CashAndCashEquivalents>
  <fsa:CashAndCashEquivalents unitRef="dkk" contextRef="ctx-4" decimals="-3">10782000</fsa:CashAndCashEquivalents>
  <fsa:CurrentAssets unitRef="dkk" contextRef="ctx-3" decimals="-3">65351000</fsa:CurrentAssets>
  <fsa:CurrentAssets unitRef="dkk" contextRef="ctx-4" decimals="-3">57123000</fsa:CurrentAssets>
  <fsa:Assets unitRef="dkk" contextRef="ctx-3" decimals="-3">65918000</fsa:Assets>
  <fsa:Assets unitRef="dkk" contextRef="ctx-4" decimals="-3">57654000</fsa:Assets>
  <fsa:ContributedCapital unitRef="dkk" contextRef="ctx-3" decimals="-3">850000</fsa:ContributedCapital>
  <fsa:ContributedCapital unitRef="dkk" contextRef="ctx-4" decimals="-3">850000</fsa:ContributedCapital>
  <fsa:RetainedEarnings unitRef="dkk" contextRef="ctx-3" decimals="-3">11256000</fsa:RetainedEarnings>
  <fsa:RetainedEarnings unitRef="dkk" contextRef="ctx-4" decimals="-3">11368000</fsa:RetainedEarnings>
  <fsa:ProposedDividendRecognisedInEquity unitRef="dkk" contextRef="ctx-3" decimals="-3">4000000</fsa:ProposedDividendRecognisedInEquity>
  <fsa:ProposedDividendRecognisedInEquity unitRef="dkk" contextRef="ctx-4" decimals="-3">2900000</fsa:ProposedDividendRecognisedInEquity>
  <fsa:Equity unitRef="dkk" contextRef="ctx-3" decimals="-3">16106000</fsa:Equity>
  <fsa:Equity unitRef="dkk" contextRef="ctx-4" decimals="-3">15118000</fsa:Equity>
  <fsa:OtherProvisions unitRef="dkk" contextRef="ctx-3" decimals="-3">6370000</fsa:OtherProvisions>
  <fsa:OtherProvisions unitRef="dkk" contextRef="ctx-4" decimals="-3">4530000</fsa:OtherProvisions>
  <fsa:Provisions unitRef="dkk" contextRef="ctx-3" decimals="-3">6370000</fsa:Provisions>
  <fsa:Provisions unitRef="dkk" contextRef="ctx-4" decimals="-3">4530000</fsa:Provisions>
  <fsa:ShorttermTradePayables unitRef="dkk" contextRef="ctx-3" decimals="-3">4622000</fsa:ShorttermTradePayables>
  <fsa:ShorttermTradePayables unitRef="dkk" contextRef="ctx-4" decimals="-3">3835000</fsa:ShorttermTradePayables>
  <fsa:ShorttermPayablesToGroupEnterprises unitRef="dkk" contextRef="ctx-3" decimals="-3">24306000</fsa:ShorttermPayablesToGroupEnterprises>
  <fsa:ShorttermPayablesToGroupEnterprises unitRef="dkk" contextRef="ctx-4" decimals="-3">23317000</fsa:ShorttermPayablesToGroupEnterprises>
  <fsa:ShorttermTaxPayables unitRef="dkk" contextRef="ctx-3" decimals="-3">1128000</fsa:ShorttermTaxPayables>
  <fsa:ShorttermTaxPayables unitRef="dkk" contextRef="ctx-4" decimals="-3">512000</fsa:ShorttermTaxPayables>
  <fsa:OtherPayablesIncludingTaxPayablesLiabilitiesOtherThanProvisionsShortterm unitRef="dkk" contextRef="ctx-3" decimals="-3">13386000</fsa:OtherPayablesIncludingTaxPayablesLiabilitiesOtherThanProvisionsShortterm>
  <fsa:OtherPayablesIncludingTaxPayablesLiabilitiesOtherThanProvisionsShortterm unitRef="dkk" contextRef="ctx-4" decimals="-3">10342000</fsa:OtherPayablesIncludingTaxPayablesLiabilitiesOtherThanProvisionsShortterm>
  <fsa:ShorttermLiabilitiesOtherThanProvisions unitRef="dkk" contextRef="ctx-3" decimals="-3">43442000</fsa:ShorttermLiabilitiesOtherThanProvisions>
  <fsa:ShorttermLiabilitiesOtherThanProvisions unitRef="dkk" contextRef="ctx-4" decimals="-3">38006000</fsa:ShorttermLiabilitiesOtherThanProvisions>
  <fsa:LiabilitiesOtherThanProvisions unitRef="dkk" contextRef="ctx-3" decimals="-3">43442000</fsa:LiabilitiesOtherThanProvisions>
  <fsa:LiabilitiesOtherThanProvisions unitRef="dkk" contextRef="ctx-4" decimals="-3">38006000</fsa:LiabilitiesOtherThanProvisions>
  <fsa:LiabilitiesAndEquity unitRef="dkk" contextRef="ctx-3" decimals="-3">65918000</fsa:LiabilitiesAndEquity>
  <fsa:LiabilitiesAndEquity unitRef="dkk" contextRef="ctx-4" decimals="-3">57654000</fsa:LiabilitiesAndEquity>
  <fsa:Equity unitRef="dkk" contextRef="ctx-5" decimals="-3">850000</fsa:Equity>
  <fsa:Equity unitRef="dkk" contextRef="ctx-8" decimals="-3">11368000</fsa:Equity>
  <fsa:Equity unitRef="dkk" contextRef="ctx-11" decimals="-3">2900000</fsa:Equity>
  <fsa:DistributedDividendsFromGroupEnterprises unitRef="dkk" contextRef="ctx-6" decimals="-3">0</fsa:DistributedDividendsFromGroupEnterprises>
  <fsa:DistributedDividendsFromGroupEnterprises unitRef="dkk" contextRef="ctx-9" decimals="-3">0</fsa:DistributedDividendsFromGroupEnterprises>
  <fsa:DistributedDividendsFromGroupEnterprises unitRef="dkk" contextRef="ctx-12" decimals="-3">-2900000</fsa:DistributedDividendsFromGroupEnterprises>
  <fsa:DistributedDividendsFromGroupEnterprises unitRef="dkk" contextRef="ctx-1" decimals="-3">-2900000</fsa:DistributedDividendsFromGroupEnterprises>
  <fsa:TransferredFromSharePremium unitRef="dkk" contextRef="ctx-6" decimals="-3">0</fsa:TransferredFromSharePremium>
  <fsa:TransferredFromSharePremium unitRef="dkk" contextRef="ctx-9" decimals="-3">-112000</fsa:TransferredFromSharePremium>
  <fsa:TransferredFromSharePremium unitRef="dkk" contextRef="ctx-12" decimals="-3">4000000</fsa:TransferredFromSharePremium>
  <fsa:TransferredFromSharePremium unitRef="dkk" contextRef="ctx-1" decimals="-3">3888000</fsa:TransferredFromSharePremium>
  <fsa:Equity unitRef="dkk" contextRef="ctx-7" decimals="-3">850000</fsa:Equity>
  <fsa:Equity unitRef="dkk" contextRef="ctx-10" decimals="-3">11256000</fsa:Equity>
  <fsa:Equity unitRef="dkk" contextRef="ctx-13" decimals="-3">4000000</fsa:Equity>
  <fsa:DisclosureOfAccountingPolicies contextRef="ctx-1" xml:lang="en">The annual report of UCB NORDIC A/S for 2023 has been prepared in accordance with the provisions applying  to  reporting  class  C  entities  with  opt-in  from  higher  accounting  class  under  the  Danish Financial Statements Act.Foreign currency translationOn initial recognition, transactions denominated in foreign currencies are translated at the exchange rates at the transaction date. Foreign exchange differences arising between the exchange rates at the transaction date and the date of payment are recognised in the income statement as financial income or financial expenses.Receivables and payables and other monetary items denominated in foreign currencies are translated at the exchange rates at the balance sheet date. The difference between the exchange rates at the balance sheet date and the date at which the receivable or payable arose or was recognised in the latest  financial  statements  is  recognised  in  the  income  statement  as  financial  income  or  financial expenses.Income statementGross ProfitWith  reference  to  section  §81  of  the  Danish  Financial  Statements  Act,  revenue  has  not  been disclosed in the annual report.RevenueRevenue from the sale of goods for resale and finished goods is recognised in the income statement when delivery and transfer of risk to the buyer has been made before year end.Revenue is recognised excluding VAT and net of discounts relating to sales.Cost of salesCost  of  sales  comprises  costs  incurred  to  generate  revenue  for  the  year. This item  also  comprises direct costs for goods for resale and changes to inventory of goods for resale.Other external costsOther  external  costs  comprise  distribution  costs  and  costs  related  to  sales,  sales  campaigns, administration, office premises, operating leases, etc.Staff costsStaff  costs  comprise  wages  and  salaries,  including  holiday  allowance,  pension  and  other  social security costs, etc., to the Company's employees, excluding reimbursements from public authorities.Financial income and expensesFinancial income and expenses comprise interest, realised and unrealised exchange adjustments as well as extra payments and refunds under the on-account taxation scheme.Tax on profit for the yearTax for the year consists of current tax for the year and deferred tax for the year. The tax attributable to  the  profit  for  the  year  is recognised  in  the  income  statement,  whereas the  tax  attributable  to  the equity transactions is recognised directly in equity.Balance sheetProperty, plant and equipmentLeasehold  improvements  and  equipment  are  measured  at  cost  less  accumulated  depreciation  and impairment losses.Cost comprises the purchase price and any costs directly attributable to the acquisition until the date on  which  the  asset  is  available  for  use.  Indirect  production  overheads  and  borrowing  costs  are  not recognised in cost.Where individual components of an item of property, plant and equipment have different useful lives, they are accounted for as separate items, which are depreciated separately.The  useful  life  and  residual  value  are  reassessed  annually.  Changes  are  treated  as  accounting estimates, and the effect on depreciation is recognised prospectively. The expected useful lives of the assets are as follows:Leasehold improvements and equipment 5 yearsGains  and  losses  on  the  disposal  of  property,  plant  and  equipment  are  stated  as  the  difference between the selling price less selling costs and the carrying amount at the date of disposal. Gains and losses are recognised in the income statement  as  other  operating  income or other operating costs, respectively.Impairment of property, plant and equipmentThe carrying amount of property, plant and equipment as well as investments in group enterprises is subject to an annual test for indications of impairment other than the decrease in value reflected by depreciation or amortisation.Impairment tests are conducted of individual assets or groups of assets when there is an indication that  they  may  be  impaired.  Write-down is  made  to  the  recoverable  amount  if  this  is  lower  than  the carrying amount.InventoriesInventories are measured at the lower of cost under the FIFO method and net realisable value.ReceivablesReceivables are measured at amortised cost.Write-down is made for bad debt losses where there is an objective indication that a receivable or a portfolio  of  receivables  has  been  impaired.  If  there  is  an  objective  indication  that  an  individual receivable has been impaired, write-down is made on an individual basis.Receivables with no objective indication of individual impairment are assessed for objective indication of impairment on a portfolio basis. The portfolios are primarily based on the debtors' registered offices and  credit  rating  in  accordance  with  the  Company's  credit  risk  management  policy.  The  objective indicators used in relation to portfolios are determined on the basis of historical loss experience.Write-downs  are  calculated  as  the  difference  between  the  carrying  amount  of  receivables  and  the present  value  of  forecast  cash  flows,  including  the  realisable  value  of  any  collateral  received.  The effective interest rate for the individual receivable or portfolio is used as discount rate.Other receivables consists of guarantee paid to third party.PrepaymentsPrepayments comprise prepaid expenses concerning subsequent financial years.Deferred tax assets and liabilitiesDeferred tax is recognised in  respect of all temporary differences between the carrying amount and the tax base of assets and liabilities.Deferred tax is measured on the basis of the tax rules and tax rates that will be effective under the legislation at the balance sheet date when the deferred tax is expected to crystallise as current tax. In cases  where  the  computation  of  the  tax  base  may  be  made  according  to  alternative  tax  rules, deferred tax is measured on the basis of the intended use of the asset and settlement of the liability, respectively.Deferred tax assets are measured at the value at which the asset is expected to be realised, either by elimination in tax on future earnings or by set off against deferred tax liabilities.Cash and cash equivalentsCash and cash equivalents comprise cash in banks.EquityDividendsDividend distribution proposed by Management for the year is disclosed as a separate equity item.ProvisionsProvisions is booked when the company has a legal or de facto obligation due to an incident occurring before or at the balance sheet date, and it is probable that capital must be ceded in order to meet the obligation.LiabilitiesPayables to credit institutions are recognized at cost at the date of borrowing, equivalent to proceeds received less transaction cost paid.Trade payables and payables to group entities are recognized at cost.Subsequently these financial liabilities are measured at cost.Other liabilities are measured at net realization value.</fsa:DisclosureOfAccountingPolicies>
  <fsa:AccountingPoliciesAreUnchangedFromPreviousPeriod contextRef="ctx-1">true</fsa:AccountingPoliciesAreUnchangedFromPreviousPeriod>
  <fsa:ExplanationOfNotDisclosingCashFlowsStatements contextRef="ctx-1" xml:lang="en">Omission of cash flow statementPursuant to section 86(4) of the Danish Financial Statements Act, no cash flow statement has been prepared.  The  Company's  cash  flows  are  included  in  the  cash  flow  statement  in  the  consolidated financial statements of UCB S.A.</fsa:ExplanationOfNotDisclosingCashFlowsStatements>
  <fsa:DisclosureOfEmployeeBenefitsExpense contextRef="ctx-1" xml:lang="en">2023 2022DKK'000Wages and Salaries   56,523    51,840 Pensions   4,486    4,014 Other social security costs   317    266   61,326    56,120 </fsa:DisclosureOfEmployeeBenefitsExpense>
  <fsa:AverageNumberOfEmployees unitRef="pure" contextRef="ctx-1" decimals="0">42</fsa:AverageNumberOfEmployees>
  <fsa:AverageNumberOfEmployees unitRef="pure" contextRef="ctx-2" decimals="0">40</fsa:AverageNumberOfEmployees>
  <fsa:InformationOnRemunerationOfManagementCategoriesAndSpecialIncentiveProgrammes contextRef="ctx-1" xml:lang="en">According to section 98 B(3) of the Danish Financial Statements Act, remuneration to the Executive Board has not been disclosed.</fsa:InformationOnRemunerationOfManagementCategoriesAndSpecialIncentiveProgrammes>
  <fsa:DisclosureOfOtherFinanceIncome contextRef="ctx-1" xml:lang="en">    Financial incomeDKK'000 2023 2022Interest received from group entities 202 20Other financial income 312 32Exchange gains 67 61581 113</fsa:DisclosureOfOtherFinanceIncome>
  <fsa:DisclosureOfOtherFinanceExpenses contextRef="ctx-1" xml:lang="en">    Financial expenses2023 2022Interest paid to group entities   745    168 Other financial expenses   34    83 Exchange losses   82    67   861    318 </fsa:DisclosureOfOtherFinanceExpenses>
  <fsa:DisclosureOfTaxExpenses contextRef="ctx-1" xml:lang="en">  Tax on profit for the year2023 2022Current tax for the year   1,736    994 Deferred tax for the year   (340)    185 Adjustment of tax concerning previous years   —    (55)   1,396    1,124 </fsa:DisclosureOfTaxExpenses>
  <fsa:TransferredToFromRetainedEarnings unitRef="dkk" contextRef="ctx-1" decimals="-3">-112000</fsa:TransferredToFromRetainedEarnings>
  <fsa:TransferredToFromRetainedEarnings unitRef="dkk" contextRef="ctx-2" decimals="-3">1104000</fsa:TransferredToFromRetainedEarnings>
  <fsa:DisclosureOfPropertyPlantAndEquipment contextRef="ctx-1" xml:lang="en">   Property, plant and equipmentLeasehold Assets under DKK'000improvements Totalconstruction&amp; equipmentCost at 1 January 2023   302    —    302 Additions for the year   —    34    34 Disposals   —    —    — Cost at 31 December 2023   302    34    336 Depreciation and impairment losses at 1 January   (299)    —    (299) 2023Depreciation and impairment losses at Depreciation   —    —    — for the yearDepreciation disposal/retirement   (3)    —    (3) Impairment loss for the year   — Depreciation and impairment losses at 31   (302)    —    (302) December 2023Carrying amount at 31 December 2023   —    34    34 </fsa:DisclosureOfPropertyPlantAndEquipment>
  <fsa:InformationOnOtherReceivables contextRef="ctx-1" xml:lang="en">   Other receivablesOther DKK'000receivablesCost at 1 January 2023 528Additions 1015Disposals   (1,010) Cost at 31 December 2023 533Carrying amount at 31 December 2023 533</fsa:InformationOnOtherReceivables>
  <fsa:ExplanationOfPrepayments contextRef="ctx-1" xml:lang="en">   PrepaymentsPrepayments comprise prepaid expenses concerning subsequent financial years.DKK'0002023 2022  179    169 </fsa:ExplanationOfPrepayments>
  <fsa:DisclosureOfProvisionsForDeferredTax contextRef="ctx-1" xml:lang="en">  Deferred tax asset2023 2022DKK'000Deferred tax at 1 January 2023   1,100    1,286 Deferred tax adjustment for the year in the income statement  341   (186)     1,441    1,100 Provisions for deferred tax relate to:Property, plant and equipment   39    50 Stock Options   1,402    1,050   1,441    1,100 </fsa:DisclosureOfProvisionsForDeferredTax>
  <fsa:DisclosureOfEquity contextRef="ctx-1" xml:lang="en">   EquityThe contributed capital consists of 850,000 shares of a nominal value of DKK 1 each.No shares carry any special rights.</fsa:DisclosureOfEquity>
  <fsa:OtherDisclosures contextRef="ctx-1" xml:lang="en">   Provisions for the share option planBased on the performance of the employee during the reference year and on his/her job level, UCB grants stock awards and stock options on April 1st in the year following the performance year.Stock  awards  are  a  promise  to  deliver  a  number  of  shares  on  the  third  anniversary  of  grant  on condition  that  the  person  remains  employed  up  to  and  including  on  the  vesting  date.  The  stock awards are granted by UCB S.A The stock awards are share based : UCB S.A buys the shares on the market, delivers them to the employee and recharges the cost to the affiliate.A Stock Option gives you the right to buy a UCB share at a certain price (exercise price) during the exercise period. Upon exercise of the stock options, UCB S.A delivers the shares to the employee. In the year of grant, UCB S.A recharges the cost of the grant to the affiliate.</fsa:OtherDisclosures>
  <fsa:DisclosureOfContingentLiabilities contextRef="ctx-1" xml:lang="en">  Contingent assets, liabilities and other financial obligationsThe Company has leases regarding company cars, printers and furniture, and has committed to give at least six months' notice on the office rental.At  31  December  2023,  the  Company  has  total  contingent  liabilities  within  one  year  of  DKK  1,970 thousand  and  after  one  year  of  1,468  DKK  thousand.  In  the  prior  year,  the  Company  had  total contingent liabilities within one year of DKK 1,674,579 thousand and after one year of DKK 893,218 thousand.</fsa:DisclosureOfContingentLiabilities>
  <fsa:DisclosureOfRelatedParties contextRef="ctx-1" xml:lang="en">   Related pary disclosuresRelated party transactionsIn  accordance  with  section  98  c(7)  of  the  Danish  Financial  Statements Act,  the  Company  has  not disclosed any related party transactions as they were conducted on an arm's length basis.Controlling interestUCB Pharma SA, Allée de la Recherche 60, 1070 Brussels, Belgium.</fsa:DisclosureOfRelatedParties>
  <fsa:InformationOnConsolidatedFinancialStatements contextRef="ctx-1" xml:lang="en">Consolidated financial statementsThe Company is included in the Group Annual Report of UCB S.A.The Group Annual Report of UCB S.A may be obtained at the following address:Allée de la Recherche 60, 1070 Brussels,Belgium </fsa:InformationOnConsolidatedFinancialStatements>
  <gsd:InformationOnTypeOfSubmittedReport contextRef="ctx-1">Annual report</gsd:InformationOnTypeOfSubmittedReport>
  <cmn:TypeOfAuditorAssistance contextRef="ctx-1">Auditor's report on audited financial statements</cmn:TypeOfAuditorAssistance>
  <gsd:ToolForPreparingTheXBRLInstanceDocument contextRef="ctx-1" xml:lang="en">ParsePort XBRL Converter</gsd:ToolForPreparingTheXBRLInstanceDocument>
  <gsd:ReportingPeriodStartDate contextRef="ctx-1">2023-01-01</gsd:ReportingPeriodStartDate>
  <gsd:ReportingPeriodEndDate contextRef="ctx-1">2023-12-31</gsd:ReportingPeriodEndDate>
  <gsd:PrecedingReportingPeriodStartDate contextRef="ctx-1">2022-01-01</gsd:PrecedingReportingPeriodStartDate>
  <gsd:PredingReportingPeriodEndDate contextRef="ctx-1">2022-12-31</gsd:PredingReportingPeriodEndDate>
  <gsd:DateOfGeneralMeeting contextRef="ctx-1">2024-05-27</gsd:DateOfGeneralMeeting>
  <fsa:ClassOfReportingEntity contextRef="ctx-1">Reporting class C, medium-size enterprise</fsa:ClassOfReportingEntity>
  <gsd:DateOfFoundationOfReportingEntity contextRef="ctx-1">2023-07-05</gsd:DateOfFoundationOfReportingEntity>
  <sob:DateOfApprovalOfAnnualReport contextRef="ctx-1">2024-05-27</sob:DateOfApprovalOfAnnualReport>
  <gsd:IdentificationNumberCvrOfSubmittingEnterprise contextRef="ctx-1">33963556</gsd:IdentificationNumberCvrOfSubmittingEnterprise>
  <gsd:NameOfSubmittingEnterprise contextRef="ctx-1" xml:lang="en">Deloitte Belastingconsulenten BV</gsd:NameOfSubmittingEnterprise>
  <gsd:AddressOfSubmittingEnterpriseStreetAndNumber contextRef="ctx-1" xml:lang="en">Weidekampsgade 6</gsd:AddressOfSubmittingEnterpriseStreetAndNumber>
  <gsd:AddressOfSubmittingEnterprisePostcodeAndTown contextRef="ctx-1" xml:lang="en">2300 København S</gsd:AddressOfSubmittingEnterprisePostcodeAndTown>
  <arr:TypeOfModifiedOpinionOnAuditedFinancialStatements contextRef="ctx-1">Opinion</arr:TypeOfModifiedOpinionOnAuditedFinancialStatements>
  <arr:TypeOfBasisForModifiedOpinionOnAuditedFinancialStatements contextRef="ctx-1">Basis for Opinion</arr:TypeOfBasisForModifiedOpinionOnAuditedFinancialStatements>
  <arr:SignatureOfAuditorsDate contextRef="ctx-1">2024-05-27</arr:SignatureOfAuditorsDate>
</xbrli:xbrl>